Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Trends in Pharmacological Sciences|July 19, 2016
Targeting WEE1 Kinase in CancerChristopher J Matheson, Donald S Backos, Philip Reigan
Oncotarget|October 30, 2016
Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitorsSteffanie L Furtek, Christopher J Matheson, Donald S Backos, et al.
Trends in Cancer|July 19, 2017
Selective Targeting of RSK Isoforms in CancerKimberly A Casalvieri, Christopher J Matheson, Donald S Backos, et al.
Bioorganic & Medicinal Chemistry|January 27, 2020
Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity studyKimberly A Casalvieri, Christopher J Matheson, Donald S Backos, et al.
Chemmedchem|June 9, 2018
Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer TherapyChristopher J Matheson, Kimberly A Casalvieri, Donald S Backos, et al.
Data in Brief|March 27, 2020
Molecular docking of substituted pteridinones and pyrimidines to the ATP-binding site of the N-terminal domain of RSK2 and associated MM/GBSA and molecular field datasetsKimberly A Casalvieri, Christopher J Matheson, Donald S Backos, et al.
ACS Chemical Biology|January 6, 2016
Strategies and Approaches of Targeting STAT3 for Cancer TreatmentSteffanie L Furtek, Donald S Backos, Christopher J Matheson, et al.
Data in Brief|October 11, 2021
Substituted pteridinones, pyrimidines, pyrrolopyrimidines, and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors: Pharmacophore modeling dataBecka M Warfield, Kimberly A Casalvieri, Christopher J Matheson, et al.
ACS Chemical Neuroscience|September 2, 2021
Evaluation of Thymidine Phosphorylase Inhibitors in Glioblastoma and Their Capacity for Temozolomide PotentiationBecka M Warfield, Christopher J Matheson, Debbie G McArthur, et al.
Bioorganic & Medicinal Chemistry|May 25, 2021
N-Substituted pyrrolopyrimidines and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitorsKimberly A Casalvieri, Christopher J Matheson, Becka M Warfield, et al.
Pageof 12